Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03426059 · ClinicalTrials.gov registry record
Mapping the Phenotype in Adults With Phelan-McDermid Syndrome
A clinical trial of Autism Spectrum Disorder and Intellectual Disability, sponsored by Boston Children's Hospital.
- Completed
- Registry status
- 24
- Enrollment target
- 6
- Study locations
NCT03426059: Completed study of Autism Spectrum Disorder and Intellectual Disability, sponsored by Boston Children's Hospital.
NCT03426059 is a study of Autism Spectrum Disorder and Intellectual Disability that has completed, run by Boston Children's Hospital. The registered enrollment target is 24 participants, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (82% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03426059, a study of Autism Spectrum Disorder and Intellectual Disability, has completed, sponsored by Boston Children's Hospital.
- COMPLETED
- Registry status
- 24 participants
- Enrollment target
- 6
- Study locations
Study Summary
The protocol aims to comprehensively define the phenotype of Phelan-McDermid Syndrome and to identify potential genetic factors, which may play a role in the variability of the disease's outcomes. The first aim involves a physical exam, a neurological exam, collection of medical history information, a clinical genetic evaluation, blood work and neuropsychological assessments. If clinically indicated, the protocol collects information from medical tests. These medical tests may include electrocardiography, echocardiography, renal ultrasonography, and renal ultrasound.
Primary Outcome
Using standardized T-scores from the Mullen Scales for Early Learning (49 to 155, where higher values represent a better outcome) or full scale IQ scores from the Stanford Binet-5 (40 to 160, where higher values represent a better outcome) to measure global cognitive ability
Conditions Studied
Interventions
- OTHER No Intervention
Study Locations (6)
California
- Stanford University - Stanford
Illinois
- Rush University Medical Center - Chicago
Maryland
- National Institutes of Health - Bethesda
Massachusetts
- Boston Children's Hospital - Boston
New York
- Icahn School of Medicine at Mount Sinai - New York
Texas
- University of Texas Southwestern - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2018-05-22 |
| Est. Completion | 2020-12-31 |
What the finished NCT03426059 record still lists
NCT03426059 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (82% lower).
The record links to 3 conditions, with Autism Spectrum Disorder appearing as the primary indexed condition, and to 1 intervention - of which No Intervention is the first listed.
NCT03426059 lists 6 locations in 6 states (California, Illinois, Maryland).
Frequently Asked Questions
What is clinical trial NCT03426059 about?
NCT03426059 is a clinical study titled "Mapping the Phenotype in Adults With Phelan-McDermid Syndrome". The protocol aims to comprehensively define the phenotype of Phelan-McDermid Syndrome and to identify potential genetic factors, which may play a role in the variability of the disease's outcomes. The first aim involves a physical exam, a neurological exam, collection of medical history information,...
What is the current status of trial NCT03426059?
This trial is currently completed. The enrollment target is 24 participants. The study started on 2018-05-22. Estimated completion is 2020-12-31.
What conditions does trial NCT03426059 study?
This clinical trial studies the following conditions: Autism Spectrum Disorder, Intellectual Disability, Phelan-McDermid Syndrome.
What interventions are being tested in trial NCT03426059?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT03426059?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03426059 being conducted?
This trial has 6 study locations across California, Illinois, Maryland, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autism Spectrum Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03426059's enrollment target sits among peer trials
24 188th of 224 higher than 31 of 224 other Autism Spectrum Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Autism Spectrum Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of an 8-Week Pickleball Program for Adults With Autism: A Feasibility Trial With a Delayed-Control Design
RECRUITING · Early Phase 1
-
Cannabidiol (CBD) in Adults With ASD
RECRUITING · Phase 1
-
COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD
RECRUITING · NA
-
Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder
RECRUITING · Phase 2
-
Emergent Multi-Class Imitation Training
RECRUITING · NA
-
Physical Activity and Community EmPOWERment Project
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI